Associate Editor, OncLive
Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com
Refining Treatment Approaches Remains a Priority in High-Risk MCL
November 20th 2023Andre Goy, MD, discusses the agents that are currently available for the treatment of patients with relapsed/refractory mantle cell lymphoma, explains the prevalence of high-risk features in this population, and emphasizes the importance of enrolling patients into clinical trials to move the needle forward.
Read More
Rucaparib Receives EC Approval for Advanced Ovarian Cancer
November 20th 2023The European Commission has approved rucaparib as first-line maintenance therapy for patients with advanced ovarian cancer, regardless of BRCA mutation status, who have responded following the completion of frontline platinum-based chemotherapy.
Read More
Tebentafusp Sustains OS Benefit in Previously Untreated, Metastatic Uveal Melanoma
November 20th 2023Paul Nathan, MBBS, PhD, MRCP, discusses the differences between cutaneous melanoma and uveal melanoma that have led to unique unmet needs for patients with the latter malignancy; updated findings from the IMCgp100-202 trial; and how these findings may influence future clinical practice.
Read More
Regulatory Decisions and Research Boost Management Strategies for Hematologic Malignancies
November 15th 2023Andrew Kuykendall, MD, discusses the current role of JAK inhibitors in myelofibrosis, the importance of chronic graft-vs-host disease awareness in patients with myeloid malignancies receiving transplant, and unmet needs for patients with chronic myelomonocytic leukemia.
Read More
Durvalumab Plus Chemo Wins Approval in China For Advanced/Metastatic Biliary Tract Cancer
November 14th 2023China’s National Medical Products Administration has approved durvalumab plus gemcitabine and cisplatin for frontline use in adult patients with locally advanced or metastatic biliary tract cancer.
Read More
Interim Management Strategies Could Aid Patients With Advanced NSCLC Awaiting Biomarker Test Results
November 13th 2023Stephen V. Liu, MD, discusses strategies for treatment and disease management for patients with advanced non–small cell lung cancer who are awaiting biomarker test results.
Read More
Phase 1 Data Support Further Investigation of RMC-6236 in KRAS-Mutant NSCLC
November 7th 2023Kathryn C. Arbour, MD, discusses the unique mechanism of action of RMC-6236, the preliminary efficacy and safety findings for this agent in patients with KRAS-mutant NSCLC, and future directions for the RMC-6236-001 trial.
Read More
BCMA-Directed Therapies Broaden Myeloma Arsenal and Could Reshape Earlier Lines of Treatment
November 6th 2023Jesus Berdeja, MD, discussed considerations when choosing between bispecific antibodies and CAR T-cell therapy for patients with multiple myeloma, clinical trials that may move CAR T-cell therapy into earlier lines, and research with agents directed at targets other than BCMA.
Read More
Strategic Active Surveillance Methods Drive Patient-Focused Prostate Cancer Care
November 3rd 2023Active surveillance can provide eligible patients with low-risk prostate cancer the opportunity to defer or avoid treatment and instead opt for routine monitoring of their disease; however, challenges arise when determining which patients should be eligible for this approach and how to maintain patient and provider protocol compliance.
Read More
Bladder Cancer Programs Offer Patients Comprehensive and Cutting-Edge Care
November 3rd 2023Gautam Jayram, MD, discusses current standards of care in the bladder cancer treatment arena, novel therapies under investigation in clinical trials that may expand the arsenal of available treatment strategies, and emphasizes the importance of implementing bladder cancer programs.
Read More
Standards of Care and Novel Therapies Converge to Propel Advances in Follicular Lymphoma
November 3rd 2023Christopher R. Flowers, MD, MS, and colleagues shed light on recent updates in the treatment armamentarium for follicular lymphoma and highlight ongoing investigations of novel agents and combinations.
Read More
Zenocutuzumab Generates Durable Responses in Advanced NRG1+ NSCLC
November 1st 2023Zenocutuzumab elicited clinical activity with a tolerable safety profile in patients with advanced non–small cell lung cancer harboring NRG1 fusions, including those with prior afatinib exposure, according to findings from the ongoing, phase 1/2 eNRGy trial.
Read More
Tazemetostat/Lenalidomide/Rituximab Regimen Enters Phase 3 Research in R/R Follicular Lymphoma
November 1st 2023Steven I. Park, MD, discusses the unique design of the SYMPHONY-1 trial, the importance of enrolling patients to the phase 3 portion of the study, and why tazemetostat in combination with lenalidomide and rituximab could represent an effective and tolerable therapeutic option for frail or older patients with relapsed/refractory follicular lymphoma.
Read More
Emerging Therapeutic Targets Shape Testing and Treatment Decisions in SCLC and NSCLC
October 31st 2023Apar Kishor Ganti, MD, discusses molecular targets to test for in lung cancer; treatment approaches for small cell lung cancer; and immunotherapy options for patients with metastatic non–small cell lung cancer in the frontline setting and beyond.
Read More
EMA Validates Application for Frontline Nivolumab Plus Chemo in Advanced Urothelial Cancer
October 30th 2023The European Medicines Agency has validated a type II variation application for the first-line combination of nivolumab and cisplatin-based chemotherapy for adult patients with unresectable or metastatic urothelial carcinoma.
Read More
Expanding Immunotherapy Armamentarium Propels Personalized HCC Treatment Approaches
October 28th 2023Richard Kim, MD, discusses the range of systemic treatment options available for patients with unresectable hepatocellular carcinoma and the importance of assessing patients for high-risk disease criteria before beginning any systemic treatment.
Read More
FDA Grants Fast Track Designation to ONCT-534 for Relapsed/Refractory mCRPC
October 27th 2023The FDA has granted fast track designation to the dual-acting androgen receptor inhibitor ONCT-534 for the treatment of patients with relapsed/refractory, metastatic castration-resistant prostate cancer that is resistant to approved androgen receptor pathway inhibitors.
Read More
Bezuclastinib Plus Sunitinib Shows Encouraging Safety and Efficacy Profile in R/R Second-Line GIST
October 25th 2023The combination of bezuclastinib and sunitinib had a tolerable safety profile and demonstrated early signals of clinical activity in patients with gastrointestinal stromal tumor.
Read More
Frontline Sobuzoxane Plus Etoposide and Rituximab is Safe and Effective in Older DLBCL Population
October 23rd 2023The combination of sobuzoxane and etoposide plus rituximab prolonged survival and showcased a tolerable safety profile in patients with previously untreated diffuse large B-cell lymphoma aged 80 years and older.
Read More
Sotorasib Plus Panitumumab Extends PFS in Refractory KRAS G12C+ mCRC
October 22nd 2023Treatment with combinations using sotorasib at multiple dose levels and panitumumab led to improved progression-free survival vs standard of care in patients with chemorefractory metastatic colorectal cancer harboring KRAS G12C mutations.
Read More
Neoadjuvant Pembrolizumab Plus Chemotherapy Boosts pCR in ER+/HER2– Breast Cancer
October 20th 2023Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy generated a statistically significant increase in pathologic complete response vs neoadjuvant placebo plus chemotherapy followed by adjuvant pembrolizumab and endocrine therapy in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.
Read More
Novel KRAS G12C Inhibitor Reflects Research Advances in NSCLC and CRC
October 19th 2023David S. Hong, MD, and David Sommerhalder, MD, discuss the unmet needs for patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC) and colorectal cancer (CRC) that prompted the initiation of the RMC-6291-001 trial; the key efficacy and safety findings with RMC-6291 in patients with NSCLC and CRC; and potential next steps for this agent.
Read More
HR+/HER2– Metastatic Breast Cancer Treatment Developments Continue to Unfold
October 19th 2023Alison K. Conlin, MD, discusses patient characteristics that drive second-line treatment decisions for patients with HR-positive, HER2-negative metastatic breast cancer; remaining needs for patients with HR-positive, HER2-negative disease; and the evolving role of oral selective estrogen receptor degraders in patients with ESR1-mutated disease.
Read More
Newer-Generation JAK Inhibitors Expand Myelofibrosis Treatment Paradigm
October 19th 2023Anthony M. Hunter, MD, discusses the roles for pacritinib, momelotinib, and fedratinib in patients with myelofibrosis; treatment sequencing with newer-generation JAK inhibitors after ruxolitinib; and the importance of having several treatment options in the second-line setting and beyond.
Read More
Individualized Treatment Selection and Sequencing Enhances Bladder and Prostate Cancer Management
October 18th 2023Daniel S. Childs, MD, and colleagues spotlight future innovations in the management of metastatic hormone-sensitive prostate cancer, treatment sequencing for metastatic urothelial carcinoma, and key data with PARP inhibitor combinations in metastatic castration-resistant prostate cancer.
Read More